321 related articles for article (PubMed ID: 25638553)
1. Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
Wilson MK; Karakasis K; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e32-42. PubMed ID: 25638553
[TBL] [Abstract][Full Text] [Related]
2. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MK; Sydes MR; Tannock IF; Oza AM
Lancet Oncol; 2015 Jan; 16(1):e43-52. PubMed ID: 25638556
[TBL] [Abstract][Full Text] [Related]
4. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
5. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
6. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
7. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
8. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
9. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
10. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
11. Translating clinical trials into meaningful outcomes.
LoRusso PM; Schnipper LE; Stewart DJ; Boerner SA; Averbuch SD; Wolf W
Clin Cancer Res; 2010 Dec; 16(24):5951-5. PubMed ID: 21169247
[TBL] [Abstract][Full Text] [Related]
12. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
13. Endpoints for clinical trials and revised assessment in neuro-oncology.
Butowski N; Chang SM
Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
[TBL] [Abstract][Full Text] [Related]
14. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
15. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Aprile G; Fontanella C; Bonotto M; Rihawi K; Lutrino SE; Ferrari L; Casagrande M; Ongaro E; Berretta M; Avallone A; Rosati G; Giuliani F; Fasola G
Oncotarget; 2015 Oct; 6(30):28716-30. PubMed ID: 26308250
[TBL] [Abstract][Full Text] [Related]
16. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.
Fiteni F; Pam A; Anota A; Vernerey D; Paget-Bailly S; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2015; 15(8):885-91. PubMed ID: 26027598
[TBL] [Abstract][Full Text] [Related]
18. General and statistical hierarchy of appropriate biologic endpoints.
Sargent D
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
[TBL] [Abstract][Full Text] [Related]
19. [Survival and quality of life: integrated endpoints].
Costantini M
Suppl Tumori; 2004; 3(4):S10-1. PubMed ID: 15206199
[No Abstract] [Full Text] [Related]
20. Endpoints in oncology clinical trials.
Kilickap S; Demirci U; Karadurmus N; Dogan M; Akinci B; Sendur MAN
J BUON; 2018 Dec; 23(7):1-6. PubMed ID: 30722104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
